



Welcome to Janssen Medical Cloud — Oncology

Janssen Medical Cloud Oncology is a platform that provides you as a healthcare professional with relevant and useful information in the field of uro-oncology, and more specifically with regard to prostate cancer.



This professional platform gives you easy access to our online and offline medical education programs, which include the most recent updates from the major conferences within your field (ASCO, ASCO-GU, ESMO, EAU, APCC).

In addition, you can access our clinical trials and the Janssen oncology portfolio from this resource with ease — including all supporting scientific studies and useful materials for your patients.

Calendar

Janssen follows the medical news closely and curates an interesting program of both online and offline scientific symposiums for your benefit.

- Prostate cancer (PC)
- Urothelial cell carcinoma (UC)






News

EUROPEAN MARKET AUTHORIZATION FOR ERLEADA (APALUTAMIDE)

On January 27, 2020, the European Commission (EMA) announced approval of ERLEADA for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with ADT. Until now, ERLEADA was only registered for adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) with a high risk of metastatic disease.

[READ MORE >](#)

Resources to discover



References

*PSA: Prostate-Specific Antigen

1. <https://www.who.int/news-room/detail/09-07-2019-who-updates-global-guidance-on-medicines-and-diagnostic-tests-to-address-health-challenges-prioritize-highly-effective-therapeutics-and-improve-affordable-access>

CP-183545 - 06-Oct-2020



YOU CAN FOLLOW US ON

CONTACT US

CONTACT US



Oncology

[HOME](#)[PORTFOLIO ▾](#)[CALENDAR](#)[SUPPORTING MATERIALS ▾](#)[CONTACT US](#)[HOME > ONCOLOGY](#)

Welcome to Janssen Medical Cloud — Oncology

Janssen Medical Cloud Oncology is a platform that provides you as a healthcare professional with relevant and useful information in the field of uro-oncology, and more specifically with regard to prostate cancer.

This professional platform gives you easy access to our online and offline medical education programs, which include the most recent updates from the major conferences within your field (ASCO, ASCO-GU, ESMO, EAU, APCC).

In addition, you can access our clinical trials and the Janssen oncology portfolio from this resource with ease — including all supporting scientific studies and useful materials for your patients.

Calendar

Janssen follows the medical news closely and curates an interesting program of both online and offline scientific symposiums for your benefit.

■ Prostate cancer (PC)

■ Urothelial cell carcinoma (UC)



News





ERLEADA (APALUTAMIDE) NOW REIMBURSED IN LUXEMBOURG

From July 2020, ERLEADA* will be reimbursed in Luxembourg (national no. 0885824) in adult men for the treatment of:

- non-metastatic castration-resistant prostate cancer (**nmCRPC**) with a high risk of developing metastatic disease
- metastatic hormone-sensitive prostate cancer (**mHSPC**) in combination with androgen deprivation therapy (ADT)

[FIND OUT MORE >](#)

Resources to discover



References

*PSA: Prostate-Specific Antigen

1. <https://www.who.int/news-room/detail/09-07-2019-who-updates-global-guidance-on-medicines-and-diagnostic-tests-to-address-health-challenges-prioritize-highly-effective-therapeutics-and-improve-affordable-access>

CP-183545 - 06-Oct-2020



YOU CAN FOLLOW US ON



CONTACT US



Prostate cancer

HOME

PORTFOLIO ▾

CALENDAR

SUPPORTING MATERIALS ▾

CONTACT US

HOME > ONCOLOGY > PROSTATE CANCER

Our prostate cancer drugs

Find more information below about our portfolio on solid tumors, consult the leading guidelines and get more information about the current clinical trials in Belgium.

ZYTICA®

Zytiga (abiraterone acetate) is an androgen synthesis inhibitor for the treatment of metastatic prostate cancer in combination with ADT (NDxHR mHSPC & mCRPC)*. Find out about the registration studies, download materials for your patients and more.

[FIND OUT MORE →](#)

ERLEADA®

Erleada (apalutamide) is a selective androgen receptor inhibitor, used with ADT for the treatment of adults with high-risk, non-metastatic castration-resistant prostate cancer (HR nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC)**. Find out about the registration studies, download materials for your patients and more.

[FIND OUT MORE →](#)

Product information



TREATMENT GUIDELINES

Here you can consult the guidelines and recommendations on the treatment of prostate cancer from the leading organizations in your field.

[VIEW NOW >](#)


CLINICAL STUDIES AND MEDICAL NEED PROGRAMS

Would you like to actively participate in the final step of the development of new medicines?
If you choose to do so, you will receive the information that you require about current clinical studies and Medical Need Programs in Belgium.

[VIEW NOW >](#)

Contact us, we are happy to help

[CONTACT US](#)

*ZYTICA® (ABIRATERONE ACETATE) IS INDICATED IN COMBINATION WITH PREDNISONE FOR:¹

- **NDx HR mHSPC:** the treatment of newly diagnosed, high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in adult men, in combination with androgen deprivation therapy (ADT) and 5 mg of prednisone
- **mCRPC post-ADT:** the treatment of metastatic castration-resistant prostate cancer (mCRPC in combination with ADT and 10 mg of prednisone) in adult men who are asymptomatic or mildly symptomatic after failure of ADT and for whom chemotherapy is not yet clinically indicated
- **mCRPC post-chemotherapy:** the treatment of mCRPC in adult men whose disease has progressed during or after a docetaxel-based chemotherapy regimen in combination with ADT and 10 mg of prednisone

**ERLEADA® (APALUTAMIDE) IS INDICATED FOR:²

- **nmCRPC:** the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) in adult men with a high risk of developing metastatic disease.
- **mHSPC:** the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).

References

ADT: Androgen deprivation therapy
mCRPC: metastatic Castration-Resistant Prostate Cancer
mHSPC: metastatic Hormone-Sensitive Prostate Cancer
mCRPC: metastatic Castration-Resistant Prostate Cancer
NDx: Newly diagnosed
HR: high-risk

1. SmPC Zytiga [🔗](#)
2. SmPC Erleada [🔗](#)

CP-183545 - 06-Oct-2020



YOU CAN FOLLOW US ON



CONTACT US

[CONTACT US](#)

Calendar

[HOME](#)[PORTFOLIO](#) ▾[CALENDAR](#)[SUPPORTING MATERIALS](#) ▾[CONTACT US](#)[HOME](#) > [ONCOLOGY](#) > [CALENDAR](#)

Event spotlight

Calendar

Janssen follows the medical news closely and puts together a handy calendar for you with the important events that Janssen organizes in your field. You will find the current highlights below.

 Prostate cancer (PC)

 Urothelial cell carcinoma (UC)



About OME

The OME forum combines expert interviews, conference reporting and round table discussions with updates of the most recent data. The OME Forum program covers a range of solid tumors, including prostate cancer and urothelial cell carcinoma.

View the complete Janssen Oncology portfolio

[!\[\]\(40770d9ed6ed4f1222ebf89a1396e8b2_img.jpg\) Discover now](#)CP-183545 - 06-Oct-2020**YOU CAN FOLLOW US ON****CONTACT US**